Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.59 USD | -4.22% |
|
-17.14% | +4.37% |
05-30 | Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million | MT |
05-23 | Oppenheimer Adjusts Price Target on Viracta Therapeutics to $11 From $13, Maintains Outperform Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.37% | 24.19M | |
+47.12% | 57.87B | |
+41.48% | 40.25B | |
-7.02% | 39.94B | |
-5.96% | 28.54B | |
+11.81% | 26.4B | |
-20.16% | 19.33B | |
+30.24% | 12.4B | |
-0.63% | 12.23B | |
+24.23% | 12.2B |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- Transcript : Viracta Therapeutics, Inc. - Special Call